Want to see IDXG full AI Analyst Report?
IDXG Stock Chart & Stats
$0.94
$0.00(0.00%)
At close: 4:00 PM EST
$0.94
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.77 - $2.40
Previous CloseN/A
Volume34.00
Average Volume (3M)11.58K
Market Cap
$42.24M
Enterprise Value$50.80
Total Cash (Recent Filing)$2.65M
Total Debt (Recent Filing)$1.08M
Price to Earnings (P/E)0.3
Beta1.39
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.23
Shares Outstanding27,700,905
10 Day Avg. Volume15,402
30 Day Avg. Volume11,583
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.14
P/FCF Ratio0.99
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Positive Free Cash FlowSustained operating and free cash flow over recent years strengthens internal funding for operations and reinvestment, reducing reliance on external capital. This cash generation supports durable operational execution and cushions the business through reimbursement timing swings common in diagnostics.
High And Stable Gross MarginsRobust gross margins near 60% indicate scalable test economics and pricing power versus variable costs. Durable margins provide room to absorb SG&A and investment, helping maintain profitability through volume fluctuations and supporting long-term margin sustainability in clinical diagnostics.
Lower Leverage And Improved Balance-sheet FlexibilityMaterial debt reduction and modest leverage improve financial flexibility, lowering interest burden and increasing capacity to fund strategic initiatives or weather reimbursement shifts. A stronger balance sheet enhances resilience in a capital-sensitive diagnostics industry.
Bears Say
Inconsistent Revenue TrendsMarked top-line declines across recent periods point to volatile demand or unfavorable test mix and reimbursement dynamics. Persistent revenue instability limits operating leverage, complicates forecasting, and can erode long-term investment capacity despite strong margins and cash flow.
Prior Negative Equity HistoryA recent recovery from multi-year negative equity signals prior capital stress and raises the risk that earnings setbacks could quickly reintroduce balance-sheet fragility. This history constrains the benefit of current improvements and warrants caution about recurrence under adverse scenarios.
Volatile Cash-flow MomentumWhile cash generation is currently positive, swings from negative to positive FCF in recent years indicate sensitivity to volume, reimbursement timing, and claims adjudication. Cash-flow volatility weakens predictability for capex or R&D investment and raises refinancing risk if volumes slip.
Interpace Diagnostics Group News
IDXG FAQ
What was Interpace Diagnostics Group’s price range in the past 12 months?
Interpace Diagnostics Group lowest stock price was $0.77 and its highest was $2.40 in the past 12 months.
What is Interpace Diagnostics Group’s market cap?
Interpace Diagnostics Group’s market cap is $42.24M.
When is Interpace Diagnostics Group’s upcoming earnings report date?
Interpace Diagnostics Group’s upcoming earnings report date is Aug 12, 2026 which is in 23 days.
How were Interpace Diagnostics Group’s earnings last quarter?
Interpace Diagnostics Group released its earnings results on May 12, 2026. The company reported $0.026 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Interpace Diagnostics Group overvalued?
According to Wall Street analysts Interpace Diagnostics Group’s price is currently Overvalued.
Does Interpace Diagnostics Group pay dividends?
Interpace Diagnostics Group does not currently pay dividends.
What is Interpace Diagnostics Group’s EPS estimate?
Interpace Diagnostics Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Interpace Diagnostics Group have?
Interpace Diagnostics Group has 27,700,905 shares outstanding.
What happened to Interpace Diagnostics Group’s price movement after its last earnings report?
Interpace Diagnostics Group reported an EPS of $0.026 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5%.
Which hedge fund is a major shareholder of Interpace Diagnostics Group?
Currently, no hedge funds are holding shares in IDXG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Interpace Diagnostics Group
Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreaticobiliary cancers. It also offers PanDNA, a molecular-only variant of PancraGEN, which delivers insights into a select number of diagnostic markers. For thyroid health, the company provides ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules. Additionally, ThyraMIR evaluates thyroid nodules for malignancy risk through the application of its proprietary microRNA gene-expression assay. Furthermore, RespriDx is a genomic diagnostic tool that aids clinicians in distinguishing between metastatic and recurrent lung cancer. Interpace Biosciences further supports the pharmaceutical and biotechnology sectors with services including pharmacogenomics testing, genotyping, biorepository solutions, and various custom scientific offerings. Its clientele primarily consists of physicians, hospitals, and clinics. Previously operating as Interpace Diagnostics Group, Inc., the company adopted its current name, Interpace Biosciences, Inc., in November 2019. Founded in 1986, its corporate headquarters are located in Parsippany, New Jersey.
Technical Analysis
―
ENDRA Life Sciences
―
Intelligent Bio Solutions
―
―
bioAffinity Technologies, Inc.
―
Ownership Overview
83.99% Insiders
<0.01% Other Institutional Investors
16.00% Public Companies and
Individual Investors